Gilead Sciences, Inc. (GILD) on Decifer

Decifer ranks GILD number 102 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 22% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 6% a year, profits grew 1,700% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Strong returns near 22% with steady widening high margins in a leading healthcare sector stand out, but revenue expected to grow only about 6% a year and momentum of 4 out of 35 leave it a quality name without a growth engine.

The current read

The evidence on GILD lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Gilead Sciences, Inc. sits in the biotech layer of the Healthcare, Biotech & Devices story.

Read the full GILD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.